ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV

The Defense Logistics Agency awarded a delivery order under basic contract SPE2DP-20-D-0002 to TEVA PHARMACEUTICALS USA, INC. for the procurement of 27 units of ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV, with a total contract value of $515,289.60. The award was made on July 14, 2026, with delivery required by July 21, 2026, to Fort Benning, Georgia, under FOB destination terms, meaning risk transfers to the government upon arrival. The vaccine is identified by NSN 6505016420106 and NDC 51285-0138-50, and must be shipped using traceable transport methods, excluding parcel post, with all packages marked with the Military Freight Identifier W25MWY61940717 and SUPP ADD HT0808 SIG:A, along with the full delivery address and Transportation Control Number. The contractor is a certified small disadvantaged women-owned business, as indicated by the Small Business designation in Block 11, and manufacturing is performed under CAGE code 0AZ22, while the contractor holds CAGE 3V8D7. Payment will be processed through the Defense Finance and Accounting Service at PO Box 182317, Columbus, OH, with invoices submitted per DFARS 252.232-7003, and the contracting officer is Melissa Rios Thomas, with John Garbarino listed as an administrative contact. Inspection and acceptance occur at the destination, with no variance permitted in the ordered quantity. The contract references the basic contract’s terms and conditions but does not replicate specific clauses, and while applicable military standards like MIL-STD-129 and MIL-STD-2073-1 are likely implied due to the nature of the shipment, they are not explicitly cited. No options, special requirements for security clearance or key personnel, or organizational conflict of interest provisions are detailed in the document, and the award was made under a delivery order structure without indication of a competitive trade-off evaluation process.